12,821 Shares in Natera, Inc. $NTRA Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp acquired a new stake in Natera, Inc. (NASDAQ:NTRA) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 12,821 shares of the medical research company’s stock, valued at approximately $3,480,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in NTRA. Horizon Investments LLC grew its holdings in shares of Natera by 22.0% during the fourth quarter. Horizon Investments LLC now owns 244 shares of the medical research company’s stock worth $56,000 after buying an additional 44 shares in the last quarter. Parallel Advisors LLC lifted its stake in shares of Natera by 5.5% in the first quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock worth $181,000 after buying an additional 47 shares in the last quarter. First Horizon Corp boosted its position in Natera by 5.5% during the first quarter. First Horizon Corp now owns 982 shares of the medical research company’s stock worth $196,000 after acquiring an additional 51 shares during the last quarter. Siemens Fonds Invest GmbH boosted its position in Natera by 3.1% during the third quarter. Siemens Fonds Invest GmbH now owns 1,804 shares of the medical research company’s stock worth $290,000 after acquiring an additional 54 shares during the last quarter. Finally, Alamea Verwaltungs GmbH grew its stake in Natera by 2.9% during the 4th quarter. Alamea Verwaltungs GmbH now owns 2,229 shares of the medical research company’s stock valued at $515,000 after acquiring an additional 62 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Analyst Ratings Changes

A number of research firms have commented on NTRA. UBS Group set a $260.00 price objective on shares of Natera in a report on Wednesday, June 24th. Citigroup upped their price target on Natera from $315.00 to $365.00 and gave the company a “buy” rating in a research report on Thursday, August 13th. Morgan Stanley reaffirmed an “overweight” rating and issued a $355.00 price target on shares of Natera in a report on Monday, August 10th. JPMorgan Chase & Co. lifted their price objective on Natera from $315.00 to $360.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Finally, BTIG Research boosted their price objective on Natera from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $319.38.

Insider Transactions at Natera

In other Natera news, Director Gail Boxer Marcus sold 11,000 shares of Natera stock in a transaction on Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the sale, the director owned 6,183 shares in the company, valued at $1,343,009.43. The trade was a 64.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Roelof Botha sold 78,000 shares of the company’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the transaction, the director directly owned 1,076,198 shares in the company, valued at approximately $237,097,181.38. This trade represents a 6.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 177,955 shares of company stock valued at $40,704,193 in the last ninety days. 5.05% of the stock is currently owned by corporate insiders.

Natera Price Performance

Shares of NTRA stock opened at $336.71 on Wednesday. The company has a market capitalization of $48.53 billion, a PE ratio of -247.58 and a beta of 1.51. The firm’s 50-day moving average is $278.79 and its two-hundred day moving average is $231.01. Natera, Inc. has a 12 month low of $157.43 and a 12 month high of $337.12.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.02. The business had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business’s revenue for the quarter was up 37.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.74) EPS. Sell-side analysts forecast that Natera, Inc. will post -1.02 EPS for the current year.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.